ClinicalTrials.govpublic full text
Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer
metastatic triple-negative breast carcinoma, 89zr-atezolizumab, pd-l1 pet, predictive biomarker, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 875137
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.